FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20240301E00019
(Amendment to DA20231003E00096)
1. Date of relevant event: 30/09/2023
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 02197
4. Name of listed corporation: Clover Biopharmaceuticals, Ltd. - B 
5. Class of shares: Ordinary Shares 
6. Number of issued shares in class: 1,295,525,233
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) Liang
(Other names) Joshua G
10. Name of director (Chinese):  
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1112The number of shares in which you are interested has increased because:
you became a member of a concert party group or a member of the concert party group acquired more of the shares
 
 
2501Other (you must describe the capacity in the Supplementary Information box)
 		 9,844         
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position240,209,01818.45
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position240,218,86218.54
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2101Beneficial owner
Long position20,122,430
2101Beneficial owner
Long position10,623,437
2501Other (you must describe the capacity in the Supplementary Information box)
Long position209,472,995
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
  USD0.000    1,592,437
Long position
4105Unlisted derivatives - Physically settled
31/03/202230/03/2032USD0.001HKD7.300  9,031,000
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
   
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
  
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: For boxes 24 and 27, pursuant to the acting-in-concert deed, Mr. Liang is deemed to be interested in 209,472,995 shares held by Dr. Liang Peng (increase of 9,844 shares resulting from vesting of RSUs on September 30, 2023). For box 28, Mr. Liang currently holds RSUs representing 1,592,437 shares pursuant to the RSU scheme.
35. Log/Serial Number of the previous form: DA20231003E00096
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 01/03/2024
(dd/mm/yyyy)